Morphosys plans 2024 application for cancer drug - share price plunges after data

The drug researcher Morphosys has achieved a breakthrough in clinical trials with its promising drug pelabresib against the rare blood cancer myelofibrosis. In a pivotal study, the Bavarians hit their...

Related Keywords

United States ,Jean Paul Kress ,Tim Demuth ,Drug Administration ,Constellation Pharmaceuticals ,Paul Kress ,Markets ,